View Main Condition: Mucopolysaccharidoses (MPS)
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.
Mutations in the IDS gene cause MPS II. The IDS gene provides instructions for producing the I2S enzyme, which is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). GAGs were originally called mucopolysaccharides, which is where this condition gets its name. Mutations in the IDS gene reduce or completely eliminate the function of the I2S enzyme. Lack of I2S enzyme activity leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS II, are called lysosomal storage disorders. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder. Researchers believe that the GAGs may also interfere with the functions of other proteins inside the lysosomes and disrupt the movement of molecules inside the cell.
MPS II occurs in approximately 1 in 100,000 to 1 in 170,000 males.
This condition is inherited in an X-linked recessive pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation would have to occur in both copies of the gene to cause the disorder. Because it is unlikely that females will have two altered copies of this gene, males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Joseph Muenzer is a Pediatrics expert in Chapel Hill, North Carolina. Muenzer has been practicing medicine for over 47 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). He is licensed to treat patients in North Carolina. Muenzer is currently accepting new patients.
Roberto Giugliani practices in Porto Alegre, Brazil. Giugliani is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). He is also highly rated in 40 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Bone Marrow Transplant, and Kidney Transplant.
Maria Escolar is a Pediatrics expert in Pittsburgh, Pennsylvania. Escolar has been practicing medicine for over 37 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). She is also highly rated in 5 other conditions, according to our data. Her top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). She is licensed to treat patients in North Carolina.
Summary: This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of DNL310, an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-spec...
Summary: RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy, dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II.
Published Date: December 01, 2008Published By: National Institutes of Health